Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebewe pharma ges.m.b.h.nfg.kg - epirubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hospira uk limited - epirubicinhydroklorid - injektionsvätska/lösning för intravesikal användning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rivopharm ltd. - epirubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - epirubicinhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva sweden ab - epirubicinhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan hospital as - epirubicinhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hameln pharma plus gmbh - epirubicinhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mylan ab - epirubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fresenius kabi oncology plc - epirubicinhydroklorid - injektions-/infusionsvätska, lösning - 2 mg/ml - epirubicinhydroklorid 2 mg aktiv substans - epirubicin

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.